Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $67.55 million.

Guidance 2024:
Revenue: $255.0 million to $265.0 million, versus the consensus of $275.3

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.